Literature DB >> 25002597

Ramucirumab approved for gastric cancer.

.   

Abstract

Based on data from the key phase III REGARD trial, the FDA approved ramucirumab as second-line therapy for patients with advanced stomach cancer and gastroesophageal junction adenocarcinoma. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25002597     DOI： 10.1158/2159-8290.CD-NB2014-069

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  3 in total

Review 1.  Ramucirumab: successfully targeting angiogenesis in gastric cancer.

Authors:  Milind Javle; Elizabeth C Smyth; Ian Chau
Journal:  Clin Cancer Res       Date:  2014-10-03       Impact factor: 12.531

Review 2.  Advances in targeted therapies and new promising targets in esophageal cancer.

Authors:  Abbes Belkhiri; Wael El-Rifai
Journal:  Oncotarget       Date:  2015-01-30

3.  Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.

Authors:  Tianwei Zhang; Lin Zhang; Shuqiong Fan; Meizhuo Zhang; Haihua Fu; Yuanjie Liu; Xiaolu Yin; Hao Chen; Liang Xie; Jingchuan Zhang; Paul R Gavine; Yi Gu; Xingzhi Ni; Xinying Su
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.